tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Financial Statements

Compare
168 Followers

Inhibikase Therapeutics Financial Overview

Inhibikase Therapeutics's market cap is currently $226.12M. The company's EPS TTM is $-2.717; its P/E ratio is ―; Inhibikase Therapeutics is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue$ 260.50K$ 123.44K$ 3.10M$ 698.47K$ 1.12M
Gross Profit$ -13.36M$ 116.72K$ -8.26M$ -195.33K$ -1.43M
Operating Income$ -20.09M$ -18.13M$ -14.77M$ -2.82M$ -5.70M
EBITDA$ -19.91M$ -18.12M$ -14.77M$ -2.82M$ -5.70M
Net Income$ -19.03M$ -17.91M$ -14.81M$ -2.88M$ -5.75M
Balance Sheet
Cash & Short-Term Investments$ 13.25M$ 23.05M$ 40.75M$ 13.95M$ 18.46K
Total Assets$ 14.51M$ 24.94M$ 42.47M$ 14.78M$ 38.25K
Total Debt$ 622.00K$ 351.29K$ 248.91K$ 319.00K$ 373.79K
Net Debt$ -8.54M$ -6.84M$ -40.50M$ -13.63M$ 355.34K
Total Liabilities$ 3.53M$ 3.90M$ 4.05M$ 5.00M$ 4.53M
Stockholders' Equity$ 10.98M$ 21.04M$ 38.42M$ 9.78M$ -4.49M
Cash Flow
Free Cash Flow$ -18.10M$ -17.59M$ -14.30M$ -1.13M$ -338.29K
Operating Cash Flow$ -18.09M$ -17.35M$ -14.30M$ -1.13M$ -338.29K
Investing Cash Flow$ 11.66M$ -16.01M$ 0.00$ 0.00$ 0.00
Financing Cash Flow$ 8.41M$ -204.77K$ 41.09M$ 15.06M$ -22.81K
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

Inhibikase Therapeutics Debt to Assets

Inhibikase Therapeutics Cash Flow

Inhibikase Therapeutics Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis